| Developers: | Halozyme Therapeutics, Roche |
| Date of the premiere of the system: | January 2024 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
2024: Start of application
On January 16, 2024, Halozyme Therapeutics announced the start of the use of Tecentrik (atezolizumab) in combination with Enhanze subcutaneous drug delivery technology based on the recombinant human hyaluronidase enzyme PH20 (rHuPH20). This is the first antitumor immunotherapy designed for subcutaneous administration.
The Tecentrique agent, owned by Roche, is a monoclonal antibody aimed at interacting with the PD-L1 protein. By inhibiting PD-L1, the drug may promote T cell activation. Atezolizumab can be used as the main element of combinations with other immunotherapeutic, targeted and chemotherapeutic drugs in the treatment of a wide range of malignancies.
The European Commission has issued permission to sell Tecentrik in combination with Enhanze technology developed by Halozyme Therapeutics. It is noted that thanks to subcutaneous administration, the time of the procedure for the delivery of the drug is reduced to 7 minutes against 30-60 minutes in the case of intravenous infusion. In addition, patients can be treated at home when using subcutaneous administration.
 | As Europe's first subcutaneous cancer immunotherapy, Tecentrik can provide a new treatment option by freeing up resources in traditional healthcare systems, says Dr. Helen Torley, President and CEO of Halozyme Therapeutics. |  |
Tecentric is indicated for use in adults. It can be used in the treatment of types of malignancies such as urothelial cancer, non-small cell lung cancer, small cell lung cancer, triple negative breast cancer, hepatocellular carcinoma and melanoma.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |